🇺🇸 FDA
Pipeline program

BGB-3111

BGB-3111-302

Phase 3 small_molecule completed

Quick answer

BGB-3111 for Waldenström's Macroglobulinemia is a Phase 3 program (small_molecule) at BeiGene with 1 ClinicalTrials.gov record(s).

Program details

Company
BeiGene
Indication
Waldenström's Macroglobulinemia
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials